- Home
- BBT vs ELVN Comparison
BBT vs ELVN Comparison
Compare BBT & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBT | ELVN |
|---|---|---|
| Founded | 1846 | 2016 |
| Country | United States | United States |
| Employees | 2050 | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BBT | ELVN |
|---|---|---|
| Price | $28.84 | $34.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $33.25 | ★ $43.40 |
| AVG Volume (30 Days) | 594.5K | ★ 684.5K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.12% | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $77.88 | N/A |
| Revenue Next Year | $4.31 | N/A |
| P/E Ratio | $29.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.81 | $14.79 |
| 52 Week High | $32.83 | $48.53 |
Technical Indicators
Market Signals| Indicator | BBT | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 47.10 | 33.24 |
| Support Level | $27.71 | $25.63 |
| Resistance Level | $29.45 | $40.62 |
| Average True Range (ATR) | 0.59 | 1.93 |
| MACD | 0.07 | -0.78 |
| Stochastic Oscillator | 60.50 | 1.47 |
Price Performance
Historical ComparisonAbout BBT Beacon Financial Corporation
Beacon Financial Corp operates as a multi-bank holding company. It offers commercial, business, and retail banking services, including a full complement of cash management products, online banking services, and consumer and residential loans.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.